

**Baxter International Inc.**  
**Key Product Line Sales**  
**Period Ending March 31, 2005**  
(unaudited)

(\$ in millions)	Q1 2005	Q1 2004	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>				
Recombinants	\$344	\$292	18%	14%
Plasma Proteins <sup>1</sup>	259	238	9%	5%
Antibody Therapy	89	80	11%	8%
Transfusion Therapies	133	140	(5%)	(8%)
Other <sup>2</sup>	77	60	28%	27%
<b>Total BioScience</b>	<b>\$902</b>	<b>\$810</b>	<b>11%</b>	<b>8%</b>
<b>Medication Delivery</b>				
IV Therapies <sup>3</sup>	\$296	\$282	5%	1%
Drug Delivery	204	188	9%	7%
Infusion Systems	230	188	22%	20%
Anesthesia	231	242	(5%)	(6%)
Other <sup>4</sup>	17	26	(35%)	(31%)
<b>Total Medication Delivery<sup>5</sup></b>	<b>\$978</b>	<b>\$926</b>	<b>6%</b>	<b>3%</b>
<b>Renal</b>				
PD Therapy	\$374	\$345	8%	4%
HD Therapy	126	124	2%	(3%)
Other	3	4	(25%)	(25%)
<b>Total Renal</b>	<b>\$503</b>	<b>\$473</b>	<b>6%</b>	<b>2%</b>
<b>TOTAL BAXTER</b>	<b>\$2,383</b>	<b>\$2,209</b>	<b>8%</b>	<b>5%</b>

<sup>1</sup> Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

<sup>2</sup> Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

<sup>3</sup> Principally includes intravenous solutions and nutritional products.

<sup>4</sup> Principally includes other hospital-distributed products.

<sup>5</sup> Sales of oncology products, which were previously included in Other, are now reported in Drug Delivery, Infusion Systems or Anesthesia, depending on the product. All prior year sales data has been reclassified to reflect this change.